Ophthalmic disease management company Harrow Inc. (NASDAQ: HROW ) on Thursday shared outcomes from a prospective, randomized, contralateral-eye clinical study .
The research evaluated the efficacy of IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3%, an ocular surface anesthetic, during same-day bilateral intravitreal injections (IVT).
According to the company, IHEEZO demonstrated statistically significant advantages at every measured time point.
Significant Reduction In Discomfort
Patients receiving IHEEZO reported an approximate 58% overall decrease in discomfort compared to their fellow eye treated with proparacaine.
Investigators noted these statistically significant improvements across all four post-procedure assessments .
The medication achieved the most substantial absolute treatment differences right after the injection, which typically represents the period of highest discomfort for the patient.
Read Next Trading IdeasViatris Sharpens Focus with Divestiture, Hikes 2026 Outlook
Viatris sells Tyrvaya to Harrow for up to $100 million, raises 2026 guidance after second-quarter earnings and revenue beat estimates.
2 min read Read this articleSustained Patient Relief
At the two-minute mark, absolute treatment differences equaled 1.62 points, with discomfort scores registering at 1.44 for IHEEZO versus 3.06 for the control solution.
Trending Get a 1% Match on Your First Deposit of $1,000+One hour post-injection, the absolute difference reached 1.56 points, as patients scored their discomfort at 1.26 with IHEEZO compared to 2.82 for the fellow eye .
This noticeable reduction in pain remained consistent and evident through the final 24-hour evaluation.
Analyst Sees Attractive Long-Term Growth For Harrow
William Blair on Thursday noted that the findings are important, as patient comfort is an important part of IVT injections, and the discomfort associated with current anesthetic and antiseptic protocols has been cited as an important contributing factor to poor compliance.
Analyst Lachlan Hanbury-Brown on Thursday wrote that these results also provide further evidence supporting a potential positive outcome from the ongoing Phase IV QUELL study expected to read out later this year, while also supporting continued adoption by retina specialists.
Harrow is advancing its position as a leader in the U.S. ophthalmic pharmaceutical market with the growth of its FDA-approved franchise. William Blair maintains the Outperform rating for the stock .
“We think the seasonality in the company’s underlying business could drive some volatility in the stock, but we believe the long-term growth outlook is attractive,” Hanbury-Brown wrote in an investor note on Thursday.
Harrow Price Action
HROW Stock Price Activity: Harrow shares were down 1.33% at $41.50 at the time of publication on Friday, according to Benzinga Pro data .
Image via Shutterstock
Read Next MoversKratos Stock Gains as International GAIA Orders Put Orbit’s Satellite Push in Focus
Kratos GAIA Orders lift KTOS shares as Orbit lands multi-million-dollar international deals for its tri-band ground station systems.
2 min read Read this article Market News and Data brought to you by Benzinga APIs© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here .
Posted In: Trading Ideas Movers News Analyst Ratings Analyst Color General Biotech Top Stories Health Care Expert Ideas